Lindsay Mitchell

Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival

Richard Kelly, Anita Hill, Louise Arnold et al. · Blood · 2011 · 516 citations · Full text

Medicine, Hematology, Pharmacotherapy +5

Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria

John Devin Peipert, Austin Kulasekararaj, Anna Gayà et al. · PLoS ONE · 2020 · 48 citations · Full text

Medicine, Hematology, Pharmacotherapy +13

Treatment outcomes of complement protein C5 inhibition in 509 UK patients with paroxysmal nocturnal hemoglobinuria

Richard Kelly, Matthew T. Holt, Jennifer Vidler et al. · Blood · 2023 · 47 citations

Life Sciences, Immunology, Pharmacology +5

Real‐world experience of pegcetacoplan in paroxysmal nocturnal hemoglobinuria

Morag Griffin, Richard Kelly, Isabelle Brindel et al. · American Journal of Hematology · 2024 · 39 citations · Full text

Medicine, Hematology, Pharmacotherapy +13

One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy: open-label extension of a randomized study

Hubert Schrezenmeier, Austin Kulasekararaj, Lindsay Mitchell et al. · Therapeutic Advances in Hematology · 2020 · 37 citations · Full text

Medicine, Hematology, Pharmacotherapy +17